Isothermal titration calorimetry binding properties of Cibacron Blue F3GA in complex with human serum albumin

Andac C. A., Çağlar Andaç S., DENİZLİ A., ANDAÇ A. M.

JOURNAL OF MOLECULAR RECOGNITION, cilt.36, sa.8, 2023 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 36 Sayı: 8
  • Basım Tarihi: 2023
  • Doi Numarası: 10.1002/jmr.3040
  • Dergi Adı: JOURNAL OF MOLECULAR RECOGNITION
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, Aerospace Database, BIOSIS, Biotechnology Research Abstracts, Chemical Abstracts Core, Communication Abstracts, MEDLINE, Metadex, Civil Engineering Abstracts
  • Anahtar Kelimeler: HSA-Ligand interactions, human serum albumin, in silico docking, isothermal titration calorimetry
  • İstanbul Üniversitesi Adresli: Evet

Özet

Binding interactions between Cibacron Blue-F3GA (CB-F3GA) and human serum albumin (HSA, at physiologically ten-fold lower concentration) was studied by isothermal titration calorimetry (ITC) and in-silico docking computations. ITC experiments revealed two separate binding sites on HSA with different binding affinities for CB-F3GA. The high-affinity binding site (PBS-II) on HSA binds CB-F3GA at nanomolar scale (K-D1 = 118 +/- 107 nM) with favorable binding enthalpy (Delta H-1(o) = -6.47 +/- 0.44 kcal/mol) and entropy (-T Delta S-1(o) = -2.98 kcal/mol) energies. CB-F3GA binds to the low-affinity binding site (PBS-I) at mu M scale (K-D2 = 31.20 +/- 18.40 mu M) with favorable binding enthalpy (Delta H-1(o) = -5.03 +/- 3.86 x 10(-2) kcal/mol) and entropy (-T Delta S-1(o) = -1.12 kcal/mol) energies. ITC binding data strongly suggest that CB-F3GA binding to PBS-II site increases the formation of dimeric-HSA clusters (N-1 = 2.43 +/- 0.50), while binding to PBS-I leads to tetrameric-HSA clusters (N-2 = 4.61 +/- 0.90). These results suggest that a higher degree of HSA aggregation upon drug binding may be expected under physiological conditions, a notion that should be further investigated for the delivery and toxicity of drug-HSA interactions.